^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Excerpt:
...Change in level of deoxyribonucleic acid (DNA) copy number in p53-related pathways`Change in level of mutation in p53-related pathways`Change in level of ribonucleic acid (RNA) expression in p53-related pathways`Change in level of protein expression in p53-related pathways...
Trial ID:
Source:
Title:
Phase II and Pharmacological Study with Wee-1 Inhibitor MK-1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer that Show Early Relapse (< 3 months) or Progression during Standard First Line Treatment with Carboplatin – Paclitaxel Combination Therapy.
Excerpt:
...p53 mutated (determined by IHC and later by sequencing) epithelial ovarian cancer2. ...
Trial ID:
More C2 evidence
Source:
Title:
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Excerpt:
...Patient Reported Outcomes`TP53 Mutations in Circulating Tumor Deoxyribonucleic Acid`Change in Levels of Circulating Deoxyribonucleic Acid TP53 Mutations by TAm-Seq`Changes in pCDC2 in Skin and Tumor Tissue`Changes in gH2AX in Skin and Tumor Tissue`Changes in pCDC2`Changes in pH2AX...
Trial ID:
Source:
Title:
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Excerpt:
...Patient Reported Outcomes`TP53 Mutations in Circulating Tumor Deoxyribonucleic Acid`Change in Levels of Circulating Deoxyribonucleic Acid TP53 Mutations by TAm-Seq`Changes in pCDC2 in Skin and Tumor Tissue`Changes in gH2AX in Skin and Tumor Tissue`Changes in pCDC2`Changes in pH2AX...
Trial ID:
Less C2 evidence
Source:
Title:
A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer
Published date:
07/01/2020
Excerpt:
We hypothesized that adavosertib, plus chemotherapy, would enhance efficacy versus placebo in TP53-mutated ovarian cancer… Adding adavosertib to chemotherapy improved ePFS (median: 7.9 [95% CI 6.9-9.9] vs 7.3 months [5.6-8.2]; HR 0.63 [95% CI 0.38-1.06]; two-sided P=0.080), meeting the predefined significance threshold (P<0.2). Clinical benefit was observed following A+C for patients with different TP53 mutation subtypes...
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1158/1078-0432.CCR-20-0219
Trial ID:
Source:
Title:
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Published date:
12/20/2016
Excerpt:
We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)-mutated ovarian cancer...Patients were treated with carboplatin....combined with AZD1775...The overall response rate was 43% (95% CI, 22% to 66%), including one patient (5%) with a prolonged complete response....this is the first report providing clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors.
Secondary therapy:
carboplatin
DOI:
10.1200/JCO.2016.67.5942
Trial ID:
